FY2028 EPS Estimates for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reduced by Analyst

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities research analysts at HC Wainwright reduced their FY2028 EPS estimates for shares of BioCryst Pharmaceuticals in a research report issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of $1.31 per share for the year, down from their prior estimate of $1.32. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.69) per share.

Other equities research analysts have also issued research reports about the stock. JMP Securities boosted their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

BioCryst Pharmaceuticals Trading Down 3.0 %

BCRX stock opened at $5.10 on Wednesday. The stock has a market cap of $1.05 billion, a PE ratio of -4.77 and a beta of 1.96. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $8.96. The company has a 50-day moving average price of $4.89 and a 200 day moving average price of $5.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to analysts’ expectations of $85.62 million. During the same period in the previous year, the business earned ($0.28) earnings per share. The business’s quarterly revenue was up 34.9% on a year-over-year basis.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock worth $106,405,000 after acquiring an additional 2,371,401 shares during the period. Avoro Capital Advisors LLC raised its position in shares of BioCryst Pharmaceuticals by 13.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock valued at $78,170,000 after buying an additional 1,500,000 shares during the last quarter. Braidwell LP raised its position in shares of BioCryst Pharmaceuticals by 6.6% in the fourth quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock valued at $34,254,000 after buying an additional 355,497 shares during the last quarter. Kynam Capital Management LP raised its position in shares of BioCryst Pharmaceuticals by 46.8% in the fourth quarter. Kynam Capital Management LP now owns 4,600,000 shares of the biotechnology company’s stock valued at $27,554,000 after buying an additional 1,466,807 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C increased its position in BioCryst Pharmaceuticals by 148.6% during the third quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock worth $23,265,000 after purchasing an additional 1,964,000 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.